[3] Fulghesu AM, Ciampelli M, Muzj G, et al
Research suggests that GLP-1 agonism may reduce inflammation, improve mitochondrial biogenesis, stimulate neurogenesis, exert neurotropic effects, and restore neuronal signaling 9 in the central nervous system
2017;12(1):e0169775
In the OASIS-4 trial, the 25 mg oral dose resulted in an average weight loss of 13.6% after 64 weeks Competition will likely heat up, as Eli Lilly is expected to submit its application to the FDA for the oral dual glucose-dependent insulinopropic polypeptide (GIP)/GLP-1 receptor agonist, orforglipron, by the end of 2025, with potential FDA approval in 2026
More serious considerations include risk of pancreatitis, gallbladder problems, kidney injury (often related to dehydration from gastrointestinal symptoms), and rare cases of medullary thyroid cancer (these medications carry a black box warning for patients with personal or family history of MTC or MEN2 syndrome)
While the above studies assessed the efficacy of lycopene in comparison to other drugs or their combination for OSF, the study by Subramaniam et al